All Stories

  1. Occurrence of venous thromboembolism in SLE: findings from a nationwide cohort and a clinical cohort in Sweden
  2. Second delivery rates and recurrence of adverse pregnancy outcomes in women with systemic lupus erythematosus: a nationwide population-based cohort study
  3. Vascular events in autoantibody-defined clusters of systemic lupus erythematosus: a 12-year prospective cohort study
  4. Associations between social determinants of health and long-term outcomes in systemic lupus erythematosus: a nationwide population-based cohort study in Sweden
  5. Dietary patterns and lupus—a new piece in an unfinished puzzle
  6. Risk of ischaemic and non-ischaemic heart failure in patients with systemic sclerosis: a population-based study
  7. Thiopurines and Intrahepatic Cholestasis of Pregnancy in Systemic Lupus Erythematosus and Inflammatory Bowel Disease Pregnancies
  8. Smoking and the risk of sarcoidosis: a systematic review and meta-analysis
  9. Temporal trends in glucocorticoids and hydroxychloroquine for treatment of systemic lupus erythematosus in Sweden
  10. Sarcoidosis Treatment Patterns in the United States
  11. GWAS identifies genetic loci, lifestyle factors and circulating biomarkers that are risk factors for sarcoidosis
  12. Development and evaluation of a Register-Based Organ Damage Index in systemic lupus erythematosus: a nationwide, population-based study from Sweden
  13. Menopausal hormone therapy and the risk of systemic lupus erythematosus and systemic sclerosis: a population-based nested case-control study
  14. Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden
  15. Response
  16. Association between maternal systemic lupus erythematosus and infant infection: a population-based cohort study in Sweden
  17. History and Familial Aggregation of Immune-Mediated Diseases in Sarcoidosis
  18. Predicting the risk of pulmonary deterioration in sarcoidosis
  19. Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case–control study in Sweden
  20. Anti-SARS-CoV-2 mRNA vaccination among patients living with SLE in Sweden: Coverage and clinical effectiveness
  21. Sick leave and disability pension following delivery in women with systemic lupus erythematosus
  22. Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
  23. Menopausal hormone therapy and risk of sarcoidosis: a population-based nested case–control study in Sweden
  24. Sarcoidosis and its relation to other immune-mediated diseases: Epidemiological insights
  25. “The chameleon among diseases” - an explorative view of sarcoidosis and identification of the consequences for affected patients and relatives using qualitative interviews
  26. Epidemiology and Damage Accrual of Systemic Lupus Erythematosus in Central Sweden: A Single‐Center Population‐Based Cohort Study Over 14 Years From Östergötland County
  27. Rheumatoid arthritis and the risk of postpartum psychiatric disorders: a Nordic population-based cohort study
  28. Sarcoidosis: Epidemiology and clinical insights
  29. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers
  30. Modifiable lifestyle risk factors for sarcoidosis: a nested case–control study
  31. Risk of gestational diabetes mellitus in relation to early pregnancy and gestational weight gain before diagnosis: A population‐based cohort study
  32. Direct modeling of relative and absolute risks in register data: Mortality risk in sarcoidosis
  33. Reproductive and hormonal risk factors for sarcoidosis: a nested case–control study
  34. Differences in disease presentation between men and women with sarcoidosis: A cohort study
  35. Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus
  36. Risk of acute myocardial infarction in sarcoidosis: A population-based cohort study from Sweden
  37. Infection hospitalisation in systemic lupus in Sweden
  38. Risk and predictors of heart failure in sarcoidosis in a population-based cohort study from Sweden
  39. Evidence of under‐reporting of early‐onset preeclampsia using register data
  40. Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids
  41. Tuberculosis in Biologic-naïve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis Characteristics
  42. Maternal Hypertensive Disorders in Pregnant Women With Systemic Lupus Erythematosus and Future Cardiovascular Outcomes
  43. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis
  44. Positive Predictive Value of Sarcoidosis Identified in an Administrative Healthcare Registry: A Validation Study
  45. Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective ‘target trial’ emulated with Swedish real‐world data
  46. Maternal and infant outcomes in sarcoidosis pregnancy: a Swedish population-based cohort study of first births
  47. Gestational weight gain and delivery outcomes: A population‐based cohort study
  48. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors
  49. Response to: ‘Neuroinflammatory events after anti-TNFα therapy’ by Kaltsonoudiset al
  50. Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study
  51. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden
  52. Are infectious diseases risk factors for sarcoidosis or a result of reverse causation? Findings from a population-based nested case–control study
  53. Sarcoidosis diagnosis and treatment in Sweden: A register-based assessment of variations by region and calendar period
  54. Sarcoidosis
  55. The Risk of Ischemic and Hemorrhagic Stroke in Patients With Idiopathic Inflammatory Myopathies: A Swedish Population‐Based Cohort Study
  56. Correspondence for “Clinical epidemiology of familial sarcoidosis: A systematic literature review”
  57. Infections increase the risk of developing Sjögren's syndrome
  58. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden
  59. Work ability before and after sarcoidosis diagnosis in Sweden
  60. Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study
  61. Epidemiology of sarcoidosis: current findings and future directions
  62. Children born to mothers with lupus are at a higher risk for childhood asthma
  63. Dr. Rossides, et al reply
  64. Sarcoidosis: Family history is a very strong risk factor – 39% of disease risk due to genetics
  65. Childhood death rates declined in Sweden from 2000 to 2014 but deaths from external causes were not always investigated
  66. Mortality is low for the majority of individuals with sarcoidosis
  67. Response to: ‘Increased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself?’ by Bruzzese and Zullo
  68. Higher mortality and lower functionality after stroke for patients with systemic lupus erythematosus
  69. Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case–control study
  70. Elevated BMI and antibodies to citrullinated proteins interact to increase rheumatoid arthritis risk and shorten time to diagnosis: A nested case–control study of women in the Nursesʼ Health Studies
  71. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study
  72. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study
  73. Cervical neoplasia in systemic lupus erythematosus: a nationwide study
  74. Medication use among pregnant women with systemic lupus erythematosus and general population comparators
  75. Early-onset Preeclampsia in Lupus Pregnancy
  76. Brief Report: Sex Ratio of Offspring Born to Women With Systemic Lupus Erythematosus or Rheumatoid Arthritis
  77. Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
  78. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden
  79. What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population‐Based Study of Maternal and Fetal Outcomes in SLE and Pre‐SLE
  80. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers
  81. Endometriosis and systemic lupus erythematosus: a population-based case–control study
  82. Case definitions in Swedish register data to identify systemic lupus erythematosus
  83. Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies
  84. Cohort profile: systemic lupus erythematosus in Sweden: the Swedish Lupus Linkage (SLINK) cohort: Figure 1
  85. Monocyte chemotactic protein-1 elevation prior to the onset of rheumatoid arthritis among women
  86. Perinatal risk factors for future SLE: a population-based nested case-control study
  87. No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment
  88. Circulating 25-hydroxyvitamin D level and risk of developing rheumatoid arthritis
  89. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study
  90. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
  91. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
  92. Patients With Ulcerative Colitis Miss More Days of Work Than the General Population, Even Following Colectomy
  93. Exposure to ultraviolet-B and risk of developing rheumatoid arthritis among women in the Nurses’ Health Study
  94. Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case–control study
  95. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study
  96. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study
  97. Ten years with biologics: to whom do data on effectiveness and safety apply?
  98. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers
  99. A Prospective Study of Periodontal Disease and Risk of Rheumatoid Arthritis
  100. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission